STOCK TITAN

Corvus Pharmaceuticals Inc - CRVS STOCK NEWS

Welcome to our dedicated news page for Corvus Pharmaceuticals (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Corvus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Corvus Pharmaceuticals's position in the market.

Rhea-AI Summary
Corvus Pharmaceuticals, Inc. will host a conference call and webcast on November 7, 2023, at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
earnings
-
Rhea-AI Summary
Corvus Pharmaceuticals plans to initiate a Phase 3 clinical trial for soquelitinib in Q1 2024, following a positive meeting with the FDA. The trial will enroll 150 patients with relapsed peripheral T cell lymphoma. The Company anticipates potential benefits in addressing a wide range of indications beyond hematologic cancers. The news is expected to positively impact the stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.53%
Tags
clinical trial
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) reports positive clinical results for soquelitinib in treating various cancers, including T cell lymphomas and solid tumors. They also announced plans for potential Phase 3 trials and highlighted preclinical data supporting the immunotherapeutic potential of soquelitinib. Additionally, updates on partner-led programs and financial results for the second quarter were provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
earnings
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. will host a conference call and webcast on August 8, 2023, at 4:30 pm ET to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) or via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.71%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
earnings
Corvus Pharmaceuticals Inc

Nasdaq:CRVS

CRVS Rankings

CRVS Stock Data

87.29M
34.40M
3.89%
39.97%
3.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Burlingame

About CRVS

corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.